Basic Information
| Drug ID | DDPD01137 |
|
| Drug Name | Levofloxacin | |
| Molecular Weight | 361.3675 | |
| Molecular Formula | C18H20FN3O4 | |
| CAS Number | 100986-85-4 | |
| SMILES | C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1 | |
| External Links | ||
| DRUGBANK | DB01137 | |
| T3DB | T3D2478 | |
| PubChem Compound | 149096 | |
| PDR | 24047 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.1 | - | 2.1 | - | DRUGBANK |
| Melting Point | 225.0 | ℃ | 225-227 | ℃ | Canadian label |
| pKa | 6.25 | - | 6.25 | - | Canadian label |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | ~100 | % | PO, oral; intravenous injection, IV; | DRUGBANK | Absorption | 50.0 | % | ~50 | % | inhalation, IH; | DRUGBANK |
| Bioavailability | 99.0 | % | ~99 | % | PO, oral; intravenous injection, IV; | DRUGBANK | Bioavailability | 99.0 | % | 99±10 | % | PO, oral; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| C Max | 6200.0 | ng/ml | 6.2±1.0 | ug/ml | PO, oral; intravenous injection, IV; | DRUGBANK | C Max | 11.5 | ng/ml | 11.5±4.0 | ug/L | PO, oral; intravenous injection, IV; | DRUGBANK | C Max | 4500.0 | ng/ml | 4.5±0.9 | mcg/ml | Oral single dose; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| T Max | 1.5 | h | 1-2 | h | PO, oral; intravenous injection, IV; | DRUGBANK | T Max | 1.0 | h | 1 | h | PO, oral; intravenous injection, IV; | DRUGBANK | T Max | 1.5 | h | 1.5 | h | PO, oral; intravenous injection, IV; | DRUGBANK | T Max | 2.5 | h | 2-3 | h | PO, oral; food; | food ↑ ; | DRUGBANK | T Max | 1.6 | h | 1.6±0.8 | h | Oral single dose; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| Metabolic | 5.0 | % | 5 | % | Urinary excretion; | DRUGBANK | |
| Clearance | 11.1 | L/h | 8.64-13.56 | L/h | apparent clearance; | DRUGBANK | Clearance | 7.1 | L/h | 5.76-8.52 | L/h | Renal clearance; | DRUGBANK | Clearance | 0.15 | L/h/kg | 2.52±0.45 | ml/min/kg | RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.11 | L/h/kg | 1.9 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.2 | L/kg | 1.09-1.26 | L/kg | Average volume of distribution; PO, oral; | DRUGBANK | Volume of Distribution | 1.4 | L/kg | 1.36±0.21 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.2 | L/kg | 1.2 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 7.0 | h | 6-8 | h | elimination half-life; | DRUGBANK | Half-life | 7.0 | h | 7±1 | h | mild renal function ↑ ;moderate renal function ↑ ;severe renal function ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 8.8 | h | 8.8 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 1803.0 | mg/kg | 1803.0 | mg/kg | PO, oral; mouse; | DRUGBANK | Toxicity LD50 | 1478.0 | mg/kg | 1478.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | Toxicity LD50 | 640.0 | mg/kg | 640.0 | mg/kg | PO, oral; Rattus, Rat; | T3DB |
| Eliminate Route | 87.0 | % | ~87 | % | Urinary excretion; Oral single dose; | DRUGBANK | Eliminate Route | 4.0 | % | <4 | % | Faeces excretion; Oral single dose; | DRUGBANK | Eliminate Route | 74.0 | % | 61-87 | % | Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 31.0 | % | 24-38 | % | plasma proteins; | Plasma Concentration → ; | DRUGBANK | Protein Binding | 31.0 | % | 24-38 | % | adults; Male, men; normal,healthy; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 16.0 | mg/kg/day | 16 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for infants | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for infants | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 500.0 | mg/day | 500 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 16.0 | mg/kg/day | 16 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 500.0 | mg/day | 500 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 250.0 | mg/dose | 250 | mg/dose | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for children | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 500.0 | mg/day | 500 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 16.0 | mg/kg/day | 16 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 500.0 | mg/day | 500 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 250.0 | mg/dose | 250 | mg/dose | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 20.0 | mg/kg/day | 20 | mg/kg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adolescents | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for adults | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
| Max dose for geriatric | 750.0 | mg/day | 750 | mg/day | PO, oral;intravenous injection, IV; | Levofloxacin Ophthalmic Solution | levofloxacin | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1